Vaccine Info

Menactra Meningococcal Vaccine

Authored by
Fact checked by
Robert Carlson, MD


Menactra contains N meningitidis serogroup 8 A, C, Y and W-135 capsular polysaccharide antigens individually conjugated to diphtheria toxoid 9 protein. N meningitidis A, C, Y, and W-135 strains are cultured on Mueller Hinton agar and 10 grown in Watson Scherp media containing casamino acid.


Menactra vaccine is indicated for active immunization to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y, and W-135. Menactra vaccine is approved for use in individuals 9 months through 55 years of age. Menactra vaccine does not prevent N meningitidis serogroup B disease.


Menactra is administered as an intramuscular injection.  

Primary Vaccination:

  • Children 9 through 23 months of age: Two doses, three months apart.
  • Individuals 2 through 55 years of age: A single dose.

Booster Vaccination:

  • A single booster dose may be given to individuals 15 through 55 years of age at continued risk for meningococcal disease if at least 4 years have elapsed since the prior dose.

Clinical Trials

No clinical trials found